Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer

•The maximum tolerated dose of luminespib is 55 mg/m2 when given in combination with pemetrexed at 500 mg/m2.•The objective response rate was 14% amongst patients treated at the maximum tolerated dose.•Tolerability of luminespib plus pemetrexed is limited by ocular toxicity. Luminespib (AUY922) is a...

Full description

Saved in:

Bibliographic Details
Published in:	Lung cancer (Amsterdam, Netherlands) Vol. 135; pp. 104 - 109
Main Authors:	Noor, Zorawar S., Goldman, Jonathan W., Lawler, William E., Telivala, Bijoy, Braiteh, Fadi, DiCarlo, Brian A., Kennedy, Kathleen, Adams, Brad, Wang, Xiaoyan, Jones, Benjamin, Slamon, Dennis J., Garon, Edward B.
Format:	Journal Article
Language:	English
Published:	Ireland Elsevier B.V 01-09-2019
Subjects:	Dihydrofolate Reductase (DHFR) Heat Shock Protein 90 (HSP90) Inhibitor Luminespib (AUY922) Non-small cell lung cancer (NSCLC) Pemetrexed Targeted therapy Heat Shock Protein 90 (HSP90) Inhibitor Dihydrofolate Reductase (DHFR) Luminespib (AUY922) Targeted therapy Pemetrexed Non-small cell lung cancer (NSCLC)
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•The maximum tolerated dose of luminespib is 55 mg/m2 when given in combination with pemetrexed at 500 mg/m2.•The objective response rate was 14% amongst patients treated at the maximum tolerated dose.•Tolerability of luminespib plus pemetrexed is limited by ocular toxicity. Luminespib (AUY922) is a second-generation heat shock protein 90 (HSP90) inhibitor with demonstrated activity in non-small cell lung cancer (NSCLC). Since luminespib reduces levels of dihydrofolate reductase (DHFR), a key enzymatic target of pemetrexed, we assessed the safety and tolerability of luminespib in combination with pemetrexed in patients with previously treated metastatic non-squamous non-small cell lung cancer (NSCLC). We also sought to study the pharmacokinetics and correlate tumor dihydrofolate reductase (DHFR) expression with clinical response. Patients received weekly luminespib at either 40 mg/m2, 55 mg/m2, or 70 mg/m2 according to a standard 3 + 3 dose-escalation design along with pemetrexed at 500 mg/m2 followed by an expansion at the maximum tolerated dose (MTD). Two-dose limiting toxicities (DLTs) were experienced in the 70 mg/m2 cohort, therefore the MTD was determined to be 55 mg/m2. 69% (N = 9) of patients experienced ophthalmologic toxicity related to luminespib. Maximum serum concentration (Cmax) of luminespib was associated with increased grade 2 drug related adverse events (DRAEs) (rs = 0.74, P < 0.01), with volume of distribution (VD) inversely associated with the number of DRAEs (rs = − 0.81, P = 0.004) and ophthalmologic related DRAEs (rs = − 0.65, P = 0.04). The best response was partial response in one patient for 20 months, prior to expiration of all luminespib. Amongst patients treated at the MTD, the objective response rate was 14%. In patients with previously treated metastatic NSCLC, the MTD of luminespib in combination with pemetrexed was 55 mg/m2 per week. The combination of luminespib and pemetrexed demonstrated clinical activity. Tolerability of luminespib with pemetrexed is limited by ocular toxicity.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2019.05.022